Nonbiologic Immune Suppression in Ulcerative Colitis

Gastroenterol Clin North Am. 2020 Dec;49(4):731-738. doi: 10.1016/j.gtc.2020.07.003. Epub 2020 Sep 19.

Abstract

This article reviews nonbiologic immunosuppressive agents in the induction and maintenance of remission of ulcerative colitis. Based on meta-analyses and North American guidelines, azathioprine, mercaptopurine, and methotrexate monotherapy are not recommended for induction therapy. Thiopurines are recommended in combination with infliximab. Tofacitinib has been shown to be an effective induction agent. Cyclosporine or tacrolimus are calcineurin inhibitors that can be used as induction therapy. Thiopurine monotherapy is suggested or recommended as maintenance therapy for patients who have achieved steroid-induced remission. Methotrexate monotherapy is not recommended. Tofacitinib has been shown to be an effective maintenance agent in moderate to severe disease.

Keywords: Azathioprine; Cyclosporine; Mercaptopurine; Methotrexate; Tacrolimus; Tofacitinib; Ulcerative colitis.

Publication types

  • Review

MeSH terms

  • Azathioprine / adverse effects
  • Azathioprine / therapeutic use
  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / immunology*
  • Contraindications, Drug*
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Maintenance Chemotherapy
  • Mercaptopurine / adverse effects
  • Meta-Analysis as Topic
  • Methotrexate / adverse effects
  • Piperidines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Remission Induction

Substances

  • Glucocorticoids
  • Immunosuppressive Agents
  • Piperidines
  • Pyrimidines
  • tofacitinib
  • Mercaptopurine
  • Azathioprine
  • Methotrexate